Morgan Stanley Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its price objective lifted by equities researchers at Morgan Stanley from $190.00 to $200.00 in a research note issued to investors on Friday, Marketbeat reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target would suggest a potential upside of 15.63% from the stock’s current price.

BIIB has been the topic of a number of other research reports. Piper Sandler upped their target price on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Guggenheim upped their target price on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday, February 9th. TD Cowen upped their target price on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Finally, BMO Capital Markets boosted their price target on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $207.92.

Biogen Stock Performance

NASDAQ BIIB opened at $172.97 on Friday. The stock has a market cap of $25.39 billion, a P/E ratio of 19.63, a PEG ratio of 2.31 and a beta of 0.16. The company’s 50-day simple moving average is $186.59 and its 200 day simple moving average is $172.70. Biogen has a twelve month low of $112.18 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Large investors have recently modified their holdings of the stock. Reflection Asset Management acquired a new position in shares of Biogen during the fourth quarter worth approximately $25,000. WPG Advisers LLC lifted its position in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC lifted its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. First Horizon Corp acquired a new position in Biogen in the fourth quarter valued at approximately $30,000. Finally, WFA of San Diego LLC acquired a new position in Biogen in the second quarter valued at approximately $32,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.